Today: 10 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Applied DNA (BNBX) Stock Surges on $58M Binance BNB Crypto Bet; New Ticker Takes Effect

Applied DNA (BNBX) Stock Surges on $58M Binance BNB Crypto Bet; New Ticker Takes Effect

Recent Market Performance Applied DNA’s share price has been extremely volatile amid its strategic shifts. According to market data, BNBX closed at $3.42 on Oct. 21 (down 2.0% that day) marketscreener.com. It then jumped after hours on Oct. 22 with news of the PIPE closing, trading around $4.49 by 8:43 AM EDT on Oct. 22 benzinga.com. This recent pop follows a 31.62% surge on Oct. 6 when Nasdaq officially changed its symbol to BNBX nasdaq.com. Earlier in October the stock briefly spiked near $5.85 (intraday high) on Oct. 6 tipranks.com. In summary, BNBX has climbed from the low-$3’s to the mid-$4’s over the past week, reflecting
22 October 2025
 ·  ·  ·  ·  · 
Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year marketbeat.com – following stronger-than-expected Q2 results (earnings beat and record revenue). However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that ARCT fell about 50% as investors digested the mixed news ng.investing.com. By pre-market trading the next day it was down over 60% at roughly $9 benzinga.com. MarketBeat confirmed that Guggenheim downgraded the stock to Neutral on Oct 22 marketbeat.com. Overall,
22 October 2025
 ·  ·  ·  ·  · 
Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Benficient stock (NASDAQ: BENF) closed Oct 21 at ~$0.49 and jumped ~64% to ~$0.80 after hours when Chairman Thomas O. Hicks and Interim CEO James Silk converted $52.6 M of preferred units into Class A shares investing.com benzinga.com. The company is racing to meet Nasdaq’s listing rules (min. equity $35 M or $1 bid price). Q1 FY2026 results (ended 6/30/25) showed heavy losses (GAAP net loss $7.19/share) but CEO Silk emphasized cost cuts and new capital deals to rebuild cash globenewswire.com scr.zacks.com. Zacks maintains a $2.00 price target, implying ~300% upside scr.zacks.com, though ChartMill notes serious financial weakness (fundamental rating 1/10) chartmill.com.
22 October 2025
 ·  ·  ·  ·  · 
Vicor Stock Skyrockets to 52-Week High After Blockbuster Q3 and AI Licensing Boom

Vicor Stock Skyrockets to 52-Week High After Blockbuster Q3 and AI Licensing Boom

Vicor Corporation (NASDAQ: VICR) shares surged after its Oct. 21 Q3 report, reaching ~$67.82 intraday on Oct. 21 (vs ~$58 the prior close) marketbeat.com. The stock is up roughly 30–35% year-to-date (fell to ~$38 low in 2024) and opened Oct 22 near $65–66. Q3 revenue was $110.4 M (up 18.5% YOY) and EPS $0.63, crushing analyst expectations investing.com marketbeat.com. Analyst firms (Craig-Hallum, Needham) upgraded VICR to Buy with ~$90 price targets, citing strong growth in high-margin IP licensing and next-gen power products gurufocus.com intellectia.ai. Investors are excited by Vicor’s role in AI and data-center power (48V and 800V systems), its recently announced ~$300 M licensing
22 October 2025
 ·  ·  ·  ·  · 
AST SpaceMobile Stock Shoots for the Stars – Verizon Deal and Satellite Breakthroughs Ignite 300% Rally

AST SpaceMobile Stock Shoots for the Stars – Verizon Deal and Satellite Breakthroughs Ignite 300% Rally

Stock Price and Recent Performance AST SpaceMobile’s stock has been one of 2025’s hottest stories. After trading around $30 in late 2024, ASTS rallied over 300% this year on a wave of positive news ts2.tech ts2.tech. In early October the stock broke out of the $40s on back-to-back ~16% jumps ts2.tech, hitting all-time highs above $74.77 ts2.tech (and briefly ~$99 on Oct 17 ts2.tech). This month’s catalyst was a partnership announcement with Verizon, which helped ASTS reach an intraday record near $100 ts2.tech. However, volatility has emerged: a dilutive share offering in early October caused a 6% pullback ts2.tech, and
22 October 2025
 ·  ·  ·  ·  · 
Will SBEV Pop or Flop? Splash Beverage Group Stock Surges on Big Deals – Analysts Weigh In

Will SBEV Pop or Flop? Splash Beverage Group Stock Surges on Big Deals – Analysts Weigh In

Stock Price and Performance Splash Beverage Group (NASDAQ: SBEV) stock has seen dramatic swings in 2025. After trading under $1 for much of early 2025, the shares climbed steeply in the spring, peaking above $13.50. By late October however, SBEV sits around $1.9, down significantly from the highs. Year-to-date it’s up roughly 70%, but this masks wild volatility: for example, a single day move of -22% on April 7 (when NYSE compliance issues hit) and a +38% jump on June 26 (when the Costa Rica water deal was announced) can be seen in the trading record. Chart snippet: FinViz data
22 October 2025
 ·  ·  ·  ·  · 
VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract

VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract

Teleradiology Contract Ignites Stock Rally On Oct. 21 VSee Health (NASDAQ: VSEE) stunned the market by announcing a landmark teleradiology services agreement with a major Level-1 trauma hospital system. The multi-year deal – which began service in June – is valued at roughly $10 million over two years, with additional $5+ million in potential bonuses for meeting volume targets streetinsider.com financialcontent.com. Management says it will double the company’s annual recurring revenue, a milestone that co-CEO Dr. Imo Aisiku hailed as “just the beginning.” In a press statement he called the deal “a game-changer for VSee Health and our shareholders,” saying
22 October 2025
 ·  ·  ·  · 
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic (same-currency) revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices. Analysts highlighted that every major segment beat. The cardiovascular
22 October 2025
 ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com. Trading reacted sharply. Novo’s Copenhagen-listed shares briefly plunged 6% on Oct. 17 when President Trump
22 October 2025
 ·  ·  ·  ·  · 
Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the year), the stock turned higher in October. TS2.Tech notes the stock “rallied strongly in recent weeks – up over 11% in October after a slower start to the year” ts2.tech. On Oct. 1, Thermo Fisher jumped about +9.8% as healthcare stocks rallied following a U.S. drug-pricing deal markets.financialcontent.com. The sector’s strength continued into early October: Biogen climbed +10.9% and Thermo +9.4% on Oct. 1 ts2.tech, and TMO again
22 October 2025
 ·  ·  ·  ·  · 
Vertiv (VRT) Stock Soars on AI Data-Center Boom and Blowout Q3 – Can the Rally Last?

Vertiv (VRT) Stock Soars on AI Data-Center Boom and Blowout Q3 – Can the Rally Last?

Record Rally and Stellar Q3 Results Vertiv’s stock has been on a tear. After years of steady growth, the share price accelerated in summer 2025 amid booming AI and data-center demand ts2.tech. By Oct. 9 the stock briefly reached a 52-week high near $180 ts2.tech. As of Oct. 22 it sits in the mid-$170s (about 50% above the start of 2025) ts2.tech. Trading volume spiked on the heels of earnings news; for example, Vertiv jumped over 5% on Oct. 10 alone. The catalyst was clearly the Oct. 22 Q3 earnings release. Vertiv reported net sales of $2.676 billion, up 29% from
22 October 2025
 ·  ·  ·  ·  · 
Oklo Stock Soars 500% on $2B Nuclear Fuel Deal – Breakthrough or Bubble?

Oklo Stock Soars 500% on $2B Nuclear Fuel Deal – Breakthrough or Bubble?

Oklo Inc. (NYSE: OKLO) is a California-based advanced nuclear startup whose stock has surged about 500–650% in 2025 finviz.com ts2.tech. It went public via a SPAC with Sam Altman’s AltC Acquisition in May 2024, raising ~$306 million oklo.com reuters.com. In mid-October 2025 Oklo announced a major fuel partnership: Europe’s newcleo will invest up to $2 billion (with Sweden’s Blykalla as a potential co-investor) to build advanced nuclear fuel factories in the U.S. oklo.com investorsobserver.com. The company has also inked 20-year power purchase agreements to supply clean power to oil producer Diamondback Energy (50 MW) and data-center firm Wyoming Hyperscale (100 MW) datacenterfrontier.com oklo.com.
22 October 2025
 ·  ·  ·  ·  · 
1 … 49 50 51 52 53 … 171
Go toTop